186 related articles for article (PubMed ID: 35502766)
1. Programmed cell death ligand 1 expression on monocytes is inversely correlated with tumour response to preoperative chemoradiotherapy for locally advanced rectal cancer.
Tojo M; Horie H; Koinuma K; Miyato H; Tsukui H; Kaneko Y; Futoh Y; Kimura Y; Takahashi K; Saito A; Ohzawa H; Yamaguchi H; Lefor AK; Sata N; Kitayama J
Colorectal Dis; 2022 Oct; 24(10):1140-1149. PubMed ID: 35502766
[TBL] [Abstract][Full Text] [Related]
2. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
3. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
4. Role of IDO expression in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy.
Takasu C; Nishi M; Yoshikawa K; Tokunaga T; Nakao T; Kashihara H; Wada Y; Yoshimoto T; Okikawa S; Yamashita S; Shimada M
BMC Cancer; 2022 Dec; 22(1):1263. PubMed ID: 36471264
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy.
Tominaga T; Akiyoshi T; Yamamoto N; Taguchi S; Mori S; Nagasaki T; Fukunaga Y; Ueno M
PLoS One; 2019; 14(2):e0212978. PubMed ID: 30807610
[TBL] [Abstract][Full Text] [Related]
6. Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer.
Bando H; Tsukada Y; Inamori K; Togashi Y; Koyama S; Kotani D; Fukuoka S; Yuki S; Komatsu Y; Homma S; Taketomi A; Uemura M; Kato T; Fukui M; Wakabayashi M; Nakamura N; Kojima M; Kawachi H; Kirsch R; Yoshida T; Suzuki Y; Sato A; Nishikawa H; Ito M; Yoshino T
Clin Cancer Res; 2022 Mar; 28(6):1136-1146. PubMed ID: 35063964
[TBL] [Abstract][Full Text] [Related]
7. Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer.
Ogura A; Akiyoshi T; Yamamoto N; Kawachi H; Ishikawa Y; Mori S; Oba K; Nagino M; Fukunaga Y; Ueno M
Eur J Cancer; 2018 Mar; 91():11-20. PubMed ID: 29328976
[TBL] [Abstract][Full Text] [Related]
8. Baseline PD-L1 expression and tumour-infiltrated lymphocyte status predict the efficacy of durvalumab consolidation therapy after chemoradiotherapy in unresectable locally advanced patients with non-small-cell lung cancer.
Shirasawa M; Yoshida T; Imabayashi T; Okuma K; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Tsuchida T; Yamamoto N; Nakayama Y; Watanabe SI; Motoi N; Ohe Y
Eur J Cancer; 2022 Feb; 162():1-10. PubMed ID: 34936940
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers.
Chiang SF; Huang CY; Ke TW; Chen TW; Lan YC; You YS; Chen WT; Chao KSC
Cancer Immunol Immunother; 2019 Feb; 68(2):283-296. PubMed ID: 30448924
[TBL] [Abstract][Full Text] [Related]
10. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8
Lim YJ; Koh J; Kim S; Jeon SR; Chie EK; Kim K; Kang GH; Han SW; Kim TY; Jeong SY; Park KJ; Wu HG
Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1216-1224. PubMed ID: 29165286
[TBL] [Abstract][Full Text] [Related]
11. Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
Machackova T; Trachtova K; Prochazka V; Grolich T; Farkasova M; Fiala L; Sefr R; Kiss I; Skrovina M; Dosoudil M; Berindan-Neagoe I; Svoboda M; Slaby O; Kala Z
Cancer Genomics Proteomics; 2020; 17(3):249-257. PubMed ID: 32345666
[TBL] [Abstract][Full Text] [Related]
12. Total neoadjuvant treatment and PD-1/PD-L1 checkpoint inhibitor in locally advanced rectal cancer.
Xiao W; Luo H; Yao Y; Wang Y; Liu S; Sun R; Chen G
Front Immunol; 2023; 14():1149122. PubMed ID: 37033988
[TBL] [Abstract][Full Text] [Related]
13. Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets.
Tada N; Kawai K; Tsuno NH; Ishihara S; Yamaguchi H; Sunami E; Kitayama J; Oba K; Watanabe T
World J Surg Oncol; 2015 Feb; 13():30. PubMed ID: 25890185
[TBL] [Abstract][Full Text] [Related]
14. A high number of PD-L1
Ando K; Hamada K; Shida M; Ohkuma R; Kubota Y; Horiike A; Matsui H; Ishiguro T; Hirasawa Y; Ariizumi H; Watanabe M; Onoue R; Tsurutani J; Yoshimura K; Tsunoda T; Kobayashi S; Wada S
Cancer Immunol Immunother; 2021 Feb; 70(2):337-348. PubMed ID: 32757055
[TBL] [Abstract][Full Text] [Related]
15. Impact of chemoradiotherapy on the immune-related tumour microenvironment and efficacy of anti-PD-(L)1 therapy for recurrences after chemoradiotherapy in patients with unresectable locally advanced non-small cell lung cancer.
Shirasawa M; Yoshida T; Matsumoto Y; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Watanabe SI; Ohe Y; Motoi N
Eur J Cancer; 2020 Nov; 140():28-36. PubMed ID: 33039811
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells: A promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy.
Sun W; Li G; Wan J; Zhu J; Shen W; Zhang Z
Oncotarget; 2016 Oct; 7(43):69507-69517. PubMed ID: 27486758
[TBL] [Abstract][Full Text] [Related]
17. Planning adaptive treatment by longitudinal response assessment implementing MR imaging, liquid biopsy and analysis of microenvironment during neoadjuvant treatment of rectal cancer (PRIMO).
Wurschi GW; Güllmar D; Gaßler N; Clement J; Kesselmeier M; Müller-Wurschi JJ; Settmacher U; Mothes H; Helfritzsch H; Liebe Y; Franiel T; Mäurer MA; Ernst T; Nicolay NH; Wittig A
Medicine (Baltimore); 2023 Apr; 102(17):e33575. PubMed ID: 37115093
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive evaluation of the tumor immune microenvironment and its dynamic changes in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy: From the phase II ADORE study.
Cho H; Kim JE; Hong YS; Kim SY; Kim J; Ryu YM; Kim SY; Kim TW
Oncoimmunology; 2022; 11(1):2148374. PubMed ID: 36451674
[TBL] [Abstract][Full Text] [Related]
19. Systemic inflammation-based predictors of pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
Xu N; Li W; Huang F; Yang J; Wen Z; Yin L; Zhang Y; Zhao J; Zhou R; Yang J
J Cancer Res Ther; 2022 Apr; 18(2):438-444. PubMed ID: 35645112
[TBL] [Abstract][Full Text] [Related]
20. Immunogenomic profiles associated with response to neoadjuvant chemoradiotherapy in patients with rectal cancer.
Akiyoshi T; Tanaka N; Kiyotani K; Gotoh O; Yamamoto N; Oba K; Fukunaga Y; Ueno M; Mori S
Br J Surg; 2019 Sep; 106(10):1381-1392. PubMed ID: 31197828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
